(RTTNews) - Aardvark Therapeutics, Inc. (AARD) announced Tuesday its participation in the 2025 United in Hope Conference for Prader-Willi syndrome or PWS on June 24-28 in Phoenix, Arizona.
The company will present previously disclosed Phase 2 data from its clinical trial evaluating ARD-101, an oral small-molecule therapy aimed at reducing hyperphagia or pathologic hunger in patients with PWS.
Aardvark will deliver both a poster and a five-minute oral presentation highlighting ARD-101's favorable safety profile and early efficacy signals observed in the Phase 2 study. Based on the results, the company has designed the ongoing Phase 3 HERO trial and started enrolling patients with PWS.
In addition, Aardvark's Chief Medical Officer Manasi Jaiman will participate in a clinician panel discussion.
ARD-101 is designed to suppress hunger-specific pathways that differ from appetite mechanisms, offering a new potential treatment strategy for PWS and other metabolic conditions.
Aardvark is also developing ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, to address limitations of current GLP-1 therapies for obesity.
Currently, AARD is trading at $14.61, up by 9.64 percent on the Nasdaq.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
